46 results
8-K
EX-99.1
RLYB
Rallybio Corp
9 May 24
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
8:11am
alloimmunization and FNAIT in the second half of 2024. The primary objectives of this trial are to assess the pharmacokinetics and safety
8-K
EX-99.1
RLYB
Rallybio Corp
12 Mar 24
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
8:11am
Disorders
In November 2023, Rallybio announced preliminary data from the completed multiple dose cohort of the Phase 1 safety and pharmacokinetics … (PK) study for RLYB212. The Phase 1 multiple dose cohort for RLYB212 was initiated in the first quarter of 2023 to evaluate the safety and PK
8-K
EX-99.1
RLYB
Rallybio Corp
20 Dec 23
Regulation FD Disclosure
8:15am
diseases.
The Phase 1 MAD study for RLYB116 evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous … design initiated in the first quarter of 2023 with a 4-week treatment duration to evaluate the safety, tolerability, pharmacokinetics
8-K
EX-99.1
0rmjfmwonev 5u0
9 Nov 23
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
8:10am
8-K
EX-99.1
780wt8vb3w tte8l1f
8 Aug 23
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
8:16am
424B3
ouava59myf4fy2
12 May 23
Prospectus supplement
4:50pm
8-K
EX-99.1
2oxfkxjk8
9 May 23
Rallybio Reports First Quarter 2023 Financial Results
8:11am
8-K
EX-1.1
xv2ml7
14 Nov 22
Entry into a Material Definitive Agreement
4:12pm
424B5
sjcneu1uau4qk4lh
14 Nov 22
Prospectus supplement for primary offering
8:02am
424B5
9ag9k jc5s
10 Nov 22
Prospectus supplement for primary offering
9:23am
8-K
EX-99.1
ch51 hwp4oqtmzxdz
28 Sep 22
Regulation FD Disclosure
8:15am
424B5
ozp77zxo rddv176mi
15 Aug 22
Prospectus supplement for primary offering
5:47pm
S-3
lkjz73j6qo250
8 Aug 22
Shelf registration
5:23pm